HomeCompareBTTAY vs CHD

BTTAY vs CHD: Dividend Comparison 2026

BTTAY yields 0.06% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTTAY wins by $8.9K in total portfolio value· pulled ahead in Year 9
10 years
BTTAY
BTTAY
● Live price
0.06%
Share price
$24.23
Annual div
$0.01
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.3K
Annual income
$8,071.06
Full BTTAY calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — BTTAY vs CHD

📍 BTTAY pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBTTAYCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BTTAY + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BTTAY pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BTTAY
Annual income on $10K today (after 15% tax)
$4.85/yr
After 10yr DRIP, annual income (after tax)
$6,860.40/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, BTTAY beats the other by $5,761.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BTTAY + CHD for your $10,000?

BTTAY: 50%CHD: 50%
100% CHD50/50100% BTTAY
Portfolio after 10yr
$30.8K
Annual income
$4,681.78/yr
Blended yield
15.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

BTTAY
No analyst data
Altman Z
1.8
Piotroski
4/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BTTAY buys
0
CHD buys
0
No recent congressional trades found for BTTAY or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBTTAYCHD
Forward yield0.06%1.27%
Annual dividend / share$0.01$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%23.1%
Portfolio after 10y$35.3K$26.4K
Annual income after 10y$8,071.06$1,292.51
Total dividends collected$14.7K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BTTAY vs CHD ($10,000, DRIP)

YearBTTAY PortfolioBTTAY Income/yrCHD PortfolioCHD Income/yrGap
1$10,711$11.40$10,856$156.32$145.00CHD
2$11,484$22.83$11,811$195.24$327.00CHD
3$12,334$45.75$12,883$244.38$549.00CHD
4$13,289$91.83$14,091$306.64$802.00CHD
5$14,404$184.94$15,463$385.88$1.1KCHD
6$15,787$374.70$17,033$487.17$1.2KCHD
7$17,660$767.61$18,843$617.36$1.2KCHD
8$20,501$1,604.98$20,947$785.72$446.00CHD
9← crossover$25,419$3,482.62$23,419$1,004.91+$2.0KBTTAY
10$35,269$8,071.06$26,350$1,292.51+$8.9KBTTAY

BTTAY vs CHD: Complete Analysis 2026

BTTAYStock

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Full BTTAY Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this BTTAY vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BTTAY vs SCHDBTTAY vs JEPIBTTAY vs OBTTAY vs KOBTTAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.